HMGB1 and neoplasm: Regorafenib inhibits the PI3K/AKT/mTOR and RAF/MEK/ERK signaling cascades, thereby inducing immunogenic cell death in tumor cells and promoting the release of ATP, high-mobility group box 1(HMGB1), and other damage‐associated molecular patterns.